+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "SARS Drug"

Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 104 Pages
  • Global
From
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020 - Product Thumbnail Image

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 152 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The SARS Drug market is a subset of the larger Respiratory Drugs market, which includes treatments for a variety of respiratory illnesses. SARS Drugs are specifically designed to treat Severe Acute Respiratory Syndrome (SARS), a viral respiratory illness that first appeared in 2002. These drugs are typically antiviral medications that are used to reduce the severity of symptoms and shorten the duration of the illness. The SARS Drug market is highly competitive, with many companies developing and marketing treatments for the virus. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Johnson & Johnson. Other companies, such as Gilead Sciences, have also developed treatments for SARS. Show Less Read more